66 XiaG.ChenB.DingJ.GaoC.LuH.ShaoZ.et al (2011)
Heres how different groups responded to treatment: Race and Ethnicity : Clinical benefits were consistent across all racial and ethnic groups Type 2 Diabetes : Patients without diabetes achieved higher total body weight loss (16.9%) versus those with diabetes (9.9%) at 12 months Body Mass Index (BMI) : After two years of treatment, 52.4% of participants moved down at least one BMI category Results show that 12% of adults receiving semaglutide reached a healthy BMI of 25 kg/m or less, compared to only 1.2% in the placebo group
Among the diseases it can potentially treat are Parkinson's disease, Alzheimer's disease, and Huntington's disease
Allelic Variant in the Glucagon-like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying: A Pilot Pharmacogenetics Study. Neurogastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society, vol
Tuy nhin, tc dng chnh ca glutathion l trung ha gc t do, chng s oxy ha
When chronic inflammation is part of the research interest, KLOW is the more common choice